Exclusive Sublicense Agreement in the PRC Territory by and among Razor Genomics, Inc. (“Sublicensor”), OncoCyte Corporation (“OncoCyte”), Encore Clinical, Inc. (“Encore”) and Burning Rock Biotech Limited (“Sublicensee”) dated December 14, 2020Exclusive Sublicense Agreement • December 16th, 2020 • OncoCyte Corp • In vitro & in vivo diagnostic substances
ONCOCYTE AND BURNING ROCK EXECUTE STRATEGIC AGREEMENT TO DISTRIBUTE DETERMARX IN CHINAExclusive Distribution Agreement • December 16th, 2020 • OncoCyte Corp • In vitro & in vivo diagnostic substances
IRVINE, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) — Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, has signed an exclusive agreement in China to license DetermaRx™, its proprietary test to identify high-risk, early-stage lung cancer patients who need treatment to improve their five-year survival, to Burning Rock Biotech Limited, a $2.5 billion market cap NASDAQ-listed (BNR) company. Burning Rock is one of the fastest growing and largest companies in China’s next-generation sequencing (NGS) based cancer therapy selection market.
